Published in Ann Oncol on September 01, 1990
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol (1991) 0.82
Bioavailability and feasibility of subcutaneous 5-fluorouracil. Br J Cancer (1993) 0.75
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol (1984) 2.66
Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther (1985) 2.50
Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol (2000) 2.24
False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet (1990) 2.05
Prognostic factors in metastatic breast cancer. Cancer Clin Trials (1981) 1.96
Sudden death in cancer patient on high-dose domperidone. Lancet (1982) 1.60
VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep (1978) 1.51
Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem (1990) 1.50
Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther (1976) 1.35
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet (1984) 1.26
Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther (1984) 1.25
Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer (1985) 1.23
New agents in non-small cell lung cancer. Cancer Treat Rev (1984) 1.19
Inherited defects of hepatic drug metabolism. Semin Liver Dis (1983) 1.17
Unfavourable effects of long-term adjuvant chemotherapy with Endoxan in radically operated bronchogenic carcinoma. Eur J Cancer (1971) 1.13
Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther (1987) 1.03
Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther (1981) 1.00
Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica (1986) 1.00
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Schweiz Med Wochenschr (1982) 0.99
Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos (1996) 0.97
Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther (1991) 0.94
Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther (1982) 0.94
Ifosfamide by continuous infusion to prevent encephalopathy. Lancet (1990) 0.94
Combined chemo- and hormonal therapy in advanced breast cancer. Cancer (1977) 0.93
Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther (1985) 0.93
Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol (1986) 0.90
Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J (Clin Res Ed) (1983) 0.89
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos (1998) 0.87
Present and future projects of the International Breast Cancer Study Group. Cancer (1994) 0.86
[The oral administration of vitamin-A-acid in leukoplakias, hyperkeratoses and squamous cell carcinomas: results and tolerance]. Schweiz Med Wochenschr (1971) 0.85
Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma. Cancer Chemother Rep 3 (1973) 0.84
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther (1986) 0.84
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1999) 0.83
Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol (1999) 0.83
Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos (1998) 0.83
Treatment of metastatic testicular carcinoma with bleomycin (NSC-125066) used alone or in combination with CCNU (NSC-79037). Cancer Chemother Rep (1975) 0.83
Comparison of the Amicon Centrifree micropartition system with the Sartorius SM 13249E Centrisart I device to determine protein free phenytoin concentrations. Ther Drug Monit (1986) 0.83
Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine. Cancer (1976) 0.83
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol (1991) 0.82
The differential localization of various drug metabolizing systems within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon tetrachloride and bromobenzene. J Pharmacol Exp Ther (1981) 0.82
Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation. J Biol Chem (1990) 0.82
Polymorphic acetylation and aminopyrine demethylation in Gilbert's syndrome. Eur J Clin Invest (1978) 0.82
Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography. J Chromatogr (1982) 0.82
Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans. J Pharmacol Exp Ther (1984) 0.81
A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin. Drug Metab Dispos (1980) 0.81
[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer]. Schweiz Med Wochenschr (1982) 0.81
New drugs in small-cell lung cancer. Cancer Treat Rev (1986) 0.81
Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol (1986) 0.81
The enigma of ifosfamide encephalopathy. Ann Oncol (1992) 0.81
Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol (1991) 0.80
Short- or long-term chemotherapy for node-positive breast cancer: LMF 6 versus 18 cycles. SAKK study 27/76. Recent Results Cancer Res (1984) 0.80
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71]. Schweiz Med Wochenschr (1980) 0.79
A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs (1984) 0.79
[Colorectal cancer. Progress and unsolved problems]. Schweiz Med Wochenschr (1981) 0.79
Induction of drug-metabolizing enzymes by the enantiomers of normephenytoin in the rat. Drug Metab Dispos (1981) 0.79
[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. Schweiz Med Wochenschr (1989) 0.78
Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Cancer (1988) 0.78
Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine. Br J Clin Pharmacol (1988) 0.78
Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol (1990) 0.78
[Antiestrogens: a new endocrine treatment possibility in metastasizing breast neoplasms. Experiences of the Swiss Cooperative Cancer Study Group with tamoxifen]. Schweiz Med Wochenschr (1978) 0.78
Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol (1994) 0.78
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med Pediatr Oncol (1979) 0.78
Phenytoin therapy for epileptic children: evaluation of salivary and plasma concentrations and of methods of assessing compliance. Dev Med Child Neurol (1981) 0.78
[Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer]. Onkologie (1981) 0.78
Methylene blue and fatal encephalopathy from ackee fruit poisoning. Lancet (1999) 0.77
Defective bile acid transport in an animal model of defective debrisoquine hydroxylation. Biochem Pharmacol (1986) 0.77
Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer. Med Pediatr Oncol (1981) 0.77
[Radioimmunoscintigraphy with a 99mTc-labeled F(ab')2 fragment of a monoclonal antibody (HMW-MAA 225.28S) in 71 patients with malignant melanoma]. Schweiz Med Wochenschr (1989) 0.77
An evaluation of tamoxifen dose escalation in advanced breast cancer. Am J Clin Oncol (1982) 0.77
Hepatic metabolism of aminopyrine in patients with chronic renal failure. Clin Sci Mol Med (1978) 0.77
[New aspects in the curative treatment of breast cancer]. Schweiz Med Wochenschr (1972) 0.77
Transformation of 5-hydroperoxyeicosatetraenoic acid into dihydroxy- and cysteinyl-leukotrienes by rat hepatocytes: effects of glutathione. Mol Pharmacol (1991) 0.76
Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol (1986) 0.76
Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma. Cancer Treat Rev (1982) 0.76
Stereoselectivity of differential routes of drug metabolism: the fate of the enantiomers of [14C]mephenytoin in the dog. J Pharmacol Exp Ther (1979) 0.76
Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br J Cancer (1993) 0.76
Evaluation of instrumental, nonisotopic immunoassays (fluorescence polarization immunoassay and enzyme-multiplied immunoassay technique) for cyclosporine monitoring in whole blood after kidney and liver transplantation. Ther Drug Monit (1992) 0.76
BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy. J Natl Cancer Inst (1988) 0.75
Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine--a retrospective study. Pharmacopsychiatry (1988) 0.75
Fighting alopecia in cancer chemotherapy. Recent Results Cancer Res (1988) 0.75
Intramolecular rearrangement of ifosfamide in aqueous solutions. Lancet (1990) 0.75
[First therapeutic experience with cis-platinum(II)diamindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma]. Schweiz Med Wochenschr (1976) 0.75
Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype? Br J Pharmacol (1990) 0.75
Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia. Br Med J (1975) 0.75
Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation. Br J Clin Pharmacol (1984) 0.75
Bioavailability and feasibility of subcutaneous 5-fluorouracil. Br J Cancer (1993) 0.75
Simultaneous hormone- and chemotherapy, compared with hormone therapy followed by chemotherapy in the treatment of metastasising mammary carcinoma--preliminary results of a current study. Recent Results Cancer Res (1980) 0.75
[Therapy of acute leukemia. Results of the Swiss study group for clinical cancer research (SAKK)]. Schweiz Med Wochenschr (1974) 0.75
[Prognosis of inoperable bronchial carcinoma]. Schweiz Med Wochenschr (1974) 0.75
Failure of hydroxyurea (NSC-32065) and prednisone (NSC-10023) in the treatment of acute myelocytic leukemia. Cancer Chemother Rep (1971) 0.75
[Anaplastic small cell bronchus carcinoma. Diagnosis, treatment and prognosis]. Dtsch Med Wochenschr (1980) 0.75
[Non-small cell bronchial carcinoma. Diagnosis, treatment and prognosis]. Dtsch Med Wochenschr (1980) 0.75
[Preliminary results of a continuous study protocol with adjuvant chemotherapy in primary operable breast carcinoma]. Haematol Blood Transfus (1978) 0.75
[Chemotherapy of malignant skeletal tumors (author's transl)]. Ther Umsch (1979) 0.75
[Therapy of lymphatic systemic diseases (lymphogranulomatosis, lympho- and reticulum cell sarcoma)]. Verh Dtsch Ges Inn Med (1973) 0.75